Cardiorenal Risk Reduction (2022)
Citation: G.B. John Mancini, Eileen O’Meara, Shelley Zieroth, et al. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Can J Cardiol. 2022 Aug;1153-1167.
Guideline Table of Contents